BridgeBio Pharma, Inc. (BBIO)

Nasdaq · Pharmaceutical Preparations

One email a week from me: what it filed, which 13F holders added or cut, where its scores stand. Free.

company in Palo Alto, United States

Corporate structure

40 entities across 9 jurisdictions, 1 in offshore financial centres. Read directly from the company’s own 10-K EX-21 filed 2026-02-24 — see the exhibit.

Which other public companies file entities in the same places:

Delaware31 Netherlands2 Canada1 Cayman Islands1 France1 Germany1 Hong Kong1 Switzerland1 United Kingdom1

Subsidiaries of BridgeBio Pharma, Inc. as disclosed in its SEC filing
Entity	Jurisdiction	Note
BB Square Capital Investors I, LP	Delaware
BB Square Capital, LLC	Delaware
BB Square Holdings, LLC	Delaware
BB Square Investors GP I, LLC	Delaware
BB Square LP Investment, LLC	Delaware
BridgeBio Chemistry, Inc.	Delaware
BridgeBio Gene Therapy LLC	Delaware
BridgeBio Gene Therapy Research, Inc.	Delaware
BridgeBio Pharma LLC	Delaware
BridgeBio Services Inc.	Delaware
Calcilytix Therapeutics, Inc.	Delaware
Cyan Therapeutics, Inc.	Delaware
DTD Therapeutics, Inc.	Delaware
Eidos Therapeutics, Inc.	Delaware
CoA Therapeutics, Inc.	Delaware
Origin Biosciences, Inc.	Delaware
Adrenas Therapeutics, Inc.	Delaware
QED Therapeutics, Inc.	Delaware
Sub22, Inc.	Delaware
Ferro Therapeutics, Inc.	Delaware
Eulamin Therapeutics, Inc.	Delaware
Cantero Therapeutics, Inc.	Delaware
Venthera, Inc.	Delaware
G Protein Therapeutics, Inc.	Delaware
Molecular Skin Therapeutics, Inc.	Delaware
Phoenix Tissue Repair, Inc.	Delaware
Navire Pharma, Inc.	Delaware
ML Bio Solutions, Inc.	Delaware
Sen Therapeutics, Inc.	Delaware
Audition Therapeutics, Inc.	Delaware
BridgeBio Pharma Canada, ULC	Canada
BridgeBio Pharma Cayman	Cayman Islands	offshore centre
BridgeBio France SAS	France
BridgeBio Germany GmbH	Germany
BridgeBio Pharma (HK) Limited	Hong Kong
BridgeBio Europe B.V.	Netherlands
BridgeBio International GmbH	Switzerland
BridgeBio UK Limited	United Kingdom
Evanesco Therapeutics, Inc.	Delaware
BridgeBio Pharma Europe B.V.	Netherlands

Financial health

Two standard screens, computed from the XBRL in FY2025 against FY2024. Every test shows the numbers behind it — a score with its inputs hidden is a number you cannot check.

Piotroski F-score

2 / 8

FAILReturn on assets positiveROA -78.3%
FAILOperating cash flow positiveOCF -446M
FAILReturn on assets improving-59.1% → -78.3%
PASSCash flow exceeds earningsOCF -446M vs NI -733M
FAILLong-term debt ratio falling47.6% → 214.5% of assets
FAILCurrent ratio improving4.67 → 2.77
FAILNo share dilution186M → 192M shares
FAILGross margin improvingno gross profit reported
PASSAsset turnover improving0.24× → 0.54×

Six-year record

Year	Revenue	Net income	Free cash flow	Gross margin	Shares
FY2020	$8.2M	−$505.5M	−$407.2M	—	117,995,457
FY2021	$69.7M	−$586.5M	−$511.2M	—	144,356,619
FY2022	$77.6M	−$484.7M	−$424.3M	—	147,473,076
FY2023	$9.3M	−$653.3M	−$529.0M	—	162,791,511
FY2024	$221.9M	−$543.3M	−$521.7M	—	186,075,873
FY2025	$502.1M	−$732.9M	−$447.0M	—	191,527,482

Ownership flow

16 institutions tracked — 7 added, 8 reduced, 1 opened a new position. Active managers added 2,530,163 shares while index money cut 5,918,600.

Institutional holders of BridgeBio Pharma, Inc. and their share-count change
Manager	Kind	Shares	Change	Value
BlackRock, Inc.	Index	10,287,156	−3,920,601	$766.2M
WELLINGTON MANAGEMENT GROUP LLP	Active fund	5,308,924	+2,824,971	$395.4M
PRICE T ROWE ASSOCIATES INC /MD/	Active fund	1,726,383	−2,075,272	$128.6M
VIKING GLOBAL INVESTORS LP	Hedge fund	9,949,219	−1,893,215	$741.0M
GEODE CAPITAL MANAGEMENT, LLC	Index	3,418,419	−1,499,611	$254.7M
Point72 Asset Management, L.P.	Hedge fund	1,532,782	+1,485,582	$114.2M
JPMORGAN CHASE & CO	Active fund	2,397,995	+1,081,336	$173.2M
CITADEL ADVISORS LLC	Hedge fund	4,326,928	+936,688	$322.3M
STATE STREET CORP	Index	4,435,932	−498,388	$330.4M
RENAISSANCE TECHNOLOGIES LLC	Hedge fund	856,846	+491,074	$63.8M
FMR LLC	Active fund	2,061,307	−282,447	$153.5M
Bridgewater Associates, LP	Hedge fund	448,143	+188,684	$33.4M
MORGAN STANLEY	Active fund	1,693,652	−183,707	$126.1M
BANK OF AMERICA CORP /DE/	Active fund	1,235,380	−50,368	$92.0M
AQR CAPITAL MANAGEMENT LLC	Hedge fund	166,949	+6,837	$12.4M

NORGES BANK holds a position with no prior filing to compare against, so its change is unknown rather than zero — and it is left out of the totals above.

From 13F filings, which cover institutions managing over $100m and are filed up to 45 days after the quarter ends — so this is a considered position, not a live one, and it is not the whole shareholder register.

Capital returned

What the company actually paid out and bought back, as reported — the record behind any yield figure.

Shares repurchased

2026Q1: $82.5M
2025Q1: $48.3M
2024Q1: $0
2021Q1: $50.0M
2020Q1: $75.0M

Identity

CIK: 0001743881
SIC: 2834 · Pharmaceutical Preparations
Incorporated: DE
Headquarters: PALO ALTO, CA
Founded: 2015-01-01

Ownership

Institutional: 99.5%
Institutions: 644
Insiders: 3.9%

Ownership percentages are a vendor aggregate, not a filing — unlike everything else on this page.

Other pharmaceutical preparations companies

BridgeBio Pharma, Inc. files under SIC 2834 — all 50 pharmaceutical preparations companies compared on assets and F-score.

PFIZER INCPFE JOHNSON & JOHNSONJNJ Merck & Co., Inc.MRK AbbVie Inc.ABBV ELI LILLY & CoLLY BRISTOL MYERS SQUIBB COBMY

Questions about BridgeBio Pharma, Inc.

How many subsidiaries does BridgeBio Pharma, Inc. file with the SEC?: 40, listed in its most recent exhibit 21. They are incorporated across 9 jurisdictions, led by Delaware, Canada, Cayman Islands. 1 of them sit in offshore financial centres. That exhibit is filed with the company's annual report and is the company's own list, not an estimate.
Is BridgeBio Pharma, Inc. financially healthy?: BridgeBio Pharma, Inc. scores 2 out of 8 on the Piotroski F-score. Only 8 of the nine tests could be computed from what it filed; the rest need a prior year it has not reported. Every test and the numbers behind it are shown above, so the arithmetic is checkable rather than something you have to take on trust.
Who are the largest institutional holders of BridgeBio Pharma, Inc.?: Among the managers tracked here, the biggest positions as of the 2026-Q2 13F filings are BlackRock, Inc. (trimming), VIKING GLOBAL INVESTORS LP (trimming), WELLINGTON MANAGEMENT GROUP LLP (adding). Direction is the change in share count against that manager's own previous filing; managers with no prior filing are left out rather than counted as new buyers.

This page is one panel of the terminal

The structure map above is the Corporate Blueprint, and in the desktop it is interactive — click any entity to re-centre the map on it and walk the ownership chain. It sits alongside the screener, the scorecard and the filings lab on one desk, on your machine.

Download the terminal See pricing

Sourced from SEC EDGAR primary filings. Figures are as reported by the company and are not investment advice. Scores are standard published screens computed from those filings; every input is shown above so you can check the arithmetic.

Corporate structure

40 entities across 9 jurisdictions, 1 in offshore financial centres. Read directly from the company’s own 10-K EX-21 filed 2026-02-24 — see the exhibit.

Entity

Jurisdiction

Note

BB Square Capital Investors I, LP

Delaware

BB Square Capital, LLC

Delaware

BB Square Holdings, LLC

Delaware

BB Square Investors GP I, LLC

Delaware

BB Square LP Investment, LLC

Delaware

BridgeBio Chemistry, Inc.

Delaware

BridgeBio Gene Therapy LLC

Delaware

BridgeBio Gene Therapy Research, Inc.

Delaware

BridgeBio Pharma LLC

Delaware

BridgeBio Services Inc.

Delaware

Calcilytix Therapeutics, Inc.

Delaware

Cyan Therapeutics, Inc.

Delaware

DTD Therapeutics, Inc.

Delaware

Eidos Therapeutics, Inc.

Delaware

CoA Therapeutics, Inc.

Delaware

Origin Biosciences, Inc.

Delaware

Adrenas Therapeutics, Inc.

Delaware

QED Therapeutics, Inc.

Delaware

Sub22, Inc.

Delaware

Ferro Therapeutics, Inc.

Delaware

Eulamin Therapeutics, Inc.

Delaware

Cantero Therapeutics, Inc.

Delaware

Venthera, Inc.

Delaware

G Protein Therapeutics, Inc.

Delaware

Molecular Skin Therapeutics, Inc.

Delaware

Phoenix Tissue Repair, Inc.

Delaware

Navire Pharma, Inc.

Delaware

ML Bio Solutions, Inc.

Delaware

Sen Therapeutics, Inc.

Delaware

Audition Therapeutics, Inc.

Delaware

BridgeBio Pharma Canada, ULC

Canada

BridgeBio Pharma Cayman

Cayman Islands

offshore centre

BridgeBio France SAS

France

BridgeBio Germany GmbH

Germany

BridgeBio Pharma (HK) Limited

Hong Kong

BridgeBio Europe B.V.

Netherlands

BridgeBio International GmbH

Switzerland

BridgeBio UK Limited

United Kingdom

Evanesco Therapeutics, Inc.

Delaware

BridgeBio Pharma Europe B.V.

Netherlands

Financial health

Two standard screens, computed from the XBRL in FY2025 against FY2024. Every test shows the numbers behind it — a score with its inputs hidden is a number you cannot check.

Piotroski F-score

2 / 8

FAILReturn on assets positiveROA -78.3%
FAILOperating cash flow positiveOCF -446M
FAILReturn on assets improving-59.1% → -78.3%
PASSCash flow exceeds earningsOCF -446M vs NI -733M
FAILLong-term debt ratio falling47.6% → 214.5% of assets
FAILCurrent ratio improving4.67 → 2.77
FAILNo share dilution186M → 192M shares
FAILGross margin improvingno gross profit reported
PASSAsset turnover improving0.24× → 0.54×

Six-year record

Year	Revenue	Net income	Free cash flow	Gross margin	Shares
FY2020	$8.2M	−$505.5M	−$407.2M	—	117,995,457
FY2021	$69.7M	−$586.5M	−$511.2M	—	144,356,619
FY2022	$77.6M	−$484.7M	−$424.3M	—	147,473,076
FY2023	$9.3M	−$653.3M	−$529.0M	—	162,791,511
FY2024	$221.9M	−$543.3M	−$521.7M	—	186,075,873
FY2025	$502.1M	−$732.9M	−$447.0M	—	191,527,482

Ownership flow

16 institutions tracked — 7 added, 8 reduced, 1 opened a new position. Active managers added 2,530,163 shares while index money cut 5,918,600.

Institutional holders of BridgeBio Pharma, Inc. and their share-count change
Manager	Kind	Shares	Change	Value
BlackRock, Inc.	Index	10,287,156	−3,920,601	$766.2M
WELLINGTON MANAGEMENT GROUP LLP	Active fund	5,308,924	+2,824,971	$395.4M
PRICE T ROWE ASSOCIATES INC /MD/	Active fund	1,726,383	−2,075,272	$128.6M
VIKING GLOBAL INVESTORS LP	Hedge fund	9,949,219	−1,893,215	$741.0M
GEODE CAPITAL MANAGEMENT, LLC	Index	3,418,419	−1,499,611	$254.7M
Point72 Asset Management, L.P.	Hedge fund	1,532,782	+1,485,582	$114.2M
JPMORGAN CHASE & CO	Active fund	2,397,995	+1,081,336	$173.2M
CITADEL ADVISORS LLC	Hedge fund	4,326,928	+936,688	$322.3M
STATE STREET CORP	Index	4,435,932	−498,388	$330.4M
RENAISSANCE TECHNOLOGIES LLC	Hedge fund	856,846	+491,074	$63.8M
FMR LLC	Active fund	2,061,307	−282,447	$153.5M
Bridgewater Associates, LP	Hedge fund	448,143	+188,684	$33.4M
MORGAN STANLEY	Active fund	1,693,652	−183,707	$126.1M
BANK OF AMERICA CORP /DE/	Active fund	1,235,380	−50,368	$92.0M
AQR CAPITAL MANAGEMENT LLC	Hedge fund	166,949	+6,837	$12.4M

NORGES BANK holds a position with no prior filing to compare against, so its change is unknown rather than zero — and it is left out of the totals above.

Questions about BridgeBio Pharma, Inc.

How many subsidiaries does BridgeBio Pharma, Inc. file with the SEC?

40, listed in its most recent exhibit 21. They are incorporated across 9 jurisdictions, led by Delaware, Canada, Cayman Islands. 1 of them sit in offshore financial centres. That exhibit is filed with the company's annual report and is the company's own list, not an estimate.

Is BridgeBio Pharma, Inc. financially healthy?

BridgeBio Pharma, Inc. scores 2 out of 8 on the Piotroski F-score. Only 8 of the nine tests could be computed from what it filed; the rest need a prior year it has not reported. Every test and the numbers behind it are shown above, so the arithmetic is checkable rather than something you have to take on trust.

Who are the largest institutional holders of BridgeBio Pharma, Inc.?

Among the managers tracked here, the biggest positions as of the 2026-Q2 13F filings are BlackRock, Inc. (trimming), VIKING GLOBAL INVESTORS LP (trimming), WELLINGTON MANAGEMENT GROUP LLP (adding). Direction is the change in share count against that manager's own previous filing; managers with no prior filing are left out rather than counted as new buyers.